A detailed history of Capital International Investors transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Capital International Investors holds 2,581,172 shares of XENE stock, worth $98.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,581,172
Previous 2,475,859 4.25%
Holding current value
$98.9 Million
Previous $96.5 Million 5.22%
% of portfolio
0.02%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$36.12 - $43.96 $3.8 Million - $4.63 Million
105,313 Added 4.25%
2,581,172 $102 Million
Q1 2024

May 14, 2024

BUY
$42.66 - $50.04 $860,708 - $1.01 Million
20,176 Added 0.82%
2,475,859 $107 Million
Q4 2023

Feb 13, 2024

BUY
$28.7 - $46.46 $254,368 - $411,774
8,863 Added 0.36%
2,455,683 $113 Million
Q3 2023

Nov 13, 2023

BUY
$34.16 - $39.73 $4.26 Million - $4.96 Million
124,829 Added 5.38%
2,446,820 $83.6 Million
Q1 2023

May 15, 2023

BUY
$33.46 - $40.35 $7.44 Million - $8.97 Million
222,412 Added 10.59%
2,321,991 $83.1 Million
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $15.1 Million - $18 Million
457,071 Added 27.83%
2,099,579 $82.8 Million
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $1.85 Million - $2.39 Million
60,000 Added 3.79%
1,642,508 $59.3 Million
Q2 2022

Aug 15, 2022

BUY
$25.44 - $35.16 $18.2 Million - $25.1 Million
714,211 Added 82.25%
1,582,508 $48.1 Million
Q1 2022

May 16, 2022

SELL
$25.09 - $33.13 $4.7 Million - $6.21 Million
-187,429 Reduced 17.75%
868,297 $26.5 Million
Q1 2019

May 15, 2019

BUY
$6.39 - $10.42 $756,103 - $1.23 Million
118,326 Added 12.62%
1,055,726 $10.7 Million
Q3 2018

Nov 14, 2018

BUY
$9.0 - $14.9 $8.44 Million - $14 Million
937,400 New
937,400 $12.4 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.